Douglas J Swirsky sold $8,266 of MXCT
CHIEF FINANCIAL OFFICER at MAXCYTE, INC.. 10,142 shares at an average of $0.82, traded Mar 17, 2026, filed Mar 19, 2026.
Score components
- +22RoleCFO
- 0Trade size$8k at market
- 0Share of holdings soldSold 6.3% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +12.6%, 3m +60.7%, 6m +58.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000905148-26-001397, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 17, 2026 | SOpen-market sale Common Stock | -10,142 | $0.82 | $8,266 | 151,669 | Mar 19, 2026 |
Related signals
Other insiders at MAXCYTE, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | MAXCYTE, INC. | Rekha Hemrajani director | $22k 10,684 shares | -21% | |
| 62Notable | MAXCYTE, INC. | William W Brooke director | $65k 50,000 shares | +50% | |
| 68Notable | MAXCYTE, INC. | Richard Douglas director | $111k 80,000 shares | +53% | |
| 65Notable | MAXCYTE, INC. | Stanley C Erck director | $137k 100,000 shares | +34% | |
| 78Notable | MAXCYTE, INC. | Maher Masoud President and CEO | $103k 75,000 shares | +75% | |
| 69Notable | MAXCYTE, INC. | Douglas J Swirsky CHIEF FINANCIAL OFFICER | $65k 50,000 shares | +45% | |
| 0Weak | MAXCYTE, INC. | John Joseph Johnston director | $14k 3,000 shares | -2% | |
| 0Weak | MAXCYTE, INC. | John Joseph Johnston director | $12k 3,000 shares | -2% | |
| 0Weak | MAXCYTE, INC. | John Joseph Johnston director | $11k 3,000 shares | -2% | |
| 5Weak | MAXCYTE, INC. | Stanley C Erck director | $177k 47,689 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.